Clinical Trial

Predictive Value of CRP, Albumin, CAR, and mGPS in Treatment Outcomes of DLBCL

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 10, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
Trial Details
NCT Number NCT07057765
Lead Sponsor Ain Shams University
Conditions DLBCL - Diffuse Large B Cell Lymphoma, Markers of Inflammation
Enrollment 40 participants
Start Date 2025-05-05
Primary Completion 2026-05 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-07-10